# Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

> **NCT06034860** · PHASE1 · TERMINATED · sponsor: **Molecular Templates, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Hepatocellular Carcinoma
- Melanoma
- Renal Cell Carcinoma
- Microsatellite Instability High
- Mismatch Repair Deficiency
- Mesothelioma
- Esophageal Squamous Cell Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Urothelial Carcinoma
- Cervical Cancer

## Interventions

- **DRUG:** MT-8421
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06034860
- **Lead sponsor:** Molecular Templates, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-01
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Sponsor Termination
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06034860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06034860, "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06034860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*